New research suggests that individuals who come off popular slimming jabs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop conventional diet and exercise regimens.
Findings released in a prominent health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using such drugs must be aware of the risk of rapid weight regain when the treatment ends," stated lead investigator Dr. Susan Jebb.
This pace of recovery means a return to starting mass within about 18 months.
Comparing Approaches
The study, which examined dozens of studies involving over 9,000 of participants, contrasted the results of these new drugs with older methods.
Scientists point out that people who shed pounds through dieting usually experience a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Doctors propose the way of the drugs is key to understanding the heightened regain.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Disease?
Health authorities suggest the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals contend that, due to the significant potential of weight regain, the treatment is often life-long.
This opinion is echoed by drug manufacturers, who note that the findings "highlight the long-term character of excess weight," comparing it to managing diseases like high blood pressure.
User Experiences
Individuals who have stopped the medication report a intense return of cravings.
"I experienced a trigger activating and you become ravenous," recalled one woman.
This difficulty is worsened if patients have not adopted permanent dietary or behavioural changes during treatment.
Widespread Use
Figures suggest that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is higher among women compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and maintained weight loss relies on ongoing behavioural support.
